awmsg logo



lenalidomide (Revlimid®)


Reference No. 1585

Publication date:
21/10/2016


Appraisal information

lenalidomide (Revlimid®) 2.5 mg capsule
lenalidomide (Revlimid®) 5 mg capsule
lenalidomide (Revlimid®) 7.5 mg capsule
lenalidomide (Revlimid®) 10 mg capsule
lenalidomide (Revlimid®) 15 mg capsule
lenalidomide (Revlimid®) 20 mg capsule
lenalidomide (Revlimid®) 25 mg capsule


Company: Celgene Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 20/10/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, lenalidomide (Revlimid®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Statement of Advice (SOA)
Download